

OMEGA DIAGNOSTICS GROUP PLC
(“Omega” or the “Company” or the “Group”)

**Director/PDMR Shareholding
Exercise of Options
and Total Voting Rights**

18 February 2021

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has agreed to allot in total 450,000 new ordinary shares of 4 pence each in the capital of the Company (“**Ordinary Shares**”). This is following the exercise of share options under the Company’s Third Unapproved Scheme by William Rhodes, Non-Executive Director of the Company, at a price of 15.25p per Ordinary Share.

Following this exercise Mr. Rhodes has today sold all 450,000 Ordinary Shares at a price of 91.115 pence per Ordinary Share. Following the above transactions Mr. Rhodes holds no Ordinary Shares but holds options over a further 1,380,406 Ordinary Shares.

Application will be made to the London Stock Exchange for the 450,000 new Ordinary Shares to be admitted to trading on AIM (“**Admission**”) and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 25 February 2021.

Following Admission, the total number of Ordinary Shares in issue will be 182,208,167 and the total number of voting rights will therefore be 182,208,167. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts:

Omega Diagnostics Group PLC

Colin King, Chief Executive

Kieron Harbinson, Group Finance Director

Tel: 01259 763 030

www.omegadiagnostics.com

finnCap Ltd

Geoff Nash / Teddy Whiley (Corporate Finance)

Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus

Lianne Cawthorne

Tel: 020 7933 8780 or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014											
1 Details of the person discharging managerial responsibilities/person closely associated											
a.	Name	William Rhodes									
2 Reason for notification											
a.	Position/Status	Non-Executive Director									
b.	Initial notification/ Amendment	Initial Notification									
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor											
a.	Name	Omega Diagnostics Group Plc									
b.	LEI	2138007U9P4BTZTYIR92									
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted											
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 4 pence each ISIN: GB00B1VCP282									
b.	Nature of the transaction	Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares									
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> <th></th> </tr> </thead> <tbody> <tr> <td>15.25p</td> <td>450,000</td> <td>Purchase</td> </tr> <tr> <td>91.115p</td> <td>450,000</td> <td>Sale</td> </tr> </tbody> </table>	Price(s)	Volume(s)		15.25p	450,000	Purchase	91.115p	450,000	Sale
Price(s)	Volume(s)										
15.25p	450,000	Purchase									
91.115p	450,000	Sale									
d.	Aggregated information	As above.									

e.	Date of the transaction	18 February 2021
f.	Place of the transaction	London Stock Exchange